Table 1. Clinicopathological parameters in lung cancer patients enrolled in the present study.
| Characteristics | Total | Rab37 expression | TIMP1 expression | PKCα expression | |||||
|---|---|---|---|---|---|---|---|---|---|
| Low (%) | Preserved (%) | Low (%) | Preserved (%) | Overexpressed (%) | Low (%) | ||||
| N = 158 | 51 (32.3%) | 107 (67.7%) | 72 (45.6%) | 86 (54.4%) | 85 (53.8%) | 73 (46.2%) | |||
| Type | |||||||||
| SCC | 21 | 9 (42.9%) | 12 (57.1%) | 17 (81.0%) | 4 (19.0%) | 16 (76.2%) | 5 (23.8%) | ||
| ADC | 137 | 42 (30.7%) | 95 (69.3%) | 55 (40.1%) | 82 (59.9%)0.001 | 69 (50.4%) | 68 (49.6%)0.027 | ||
| Stage | |||||||||
| Stage I–II | 107 | 27 (25.2%) | 80 (74.8%) | 47 (43.9%) | 60 (56.1%) | 58 (54.2%) | 49 (45.8%) | ||
| Stage III–IV | 51 | 24 (47.0%) | 27 (53.0%)0.009 | 25 (49.0%) | 26 (51.0%) | 27 (53.0%) | 24 (47.0%) | ||
| T stage | |||||||||
| Stage 1–2 | 127 | 38 (29.9%) | 89 (70.1%) | 53 (41.7%) | 74 (58.3%) | 68 (53.5%) | 59 (46.5%) | ||
| Stage 3–4 | 29 | 12 (41.4%) | 17 (58.6%) | 18 (62.1%) | 11 (37.9%)0.047 | 17 (58.6%) | 12 (41.4%) | ||
| N stage | |||||||||
| N0 | 88 | 23 (26.1%) | 65 (73.9%) | 41 (46.6%) | 47 (53.4%) | 51 (58.0%) | 37 (42.0%) | ||
| > N1 | 69 | 27 (39.1%) | 42 (60.9%) | 30 (43.5%) | 39 (56.5%) | 34 (49.3%) | 35 (50.7%) | ||
| M stage | |||||||||
| M0 | 133 | 38 (28.6%) | 95 (71.4%) | 58 (43.6%) | 75 (56.4%) | 66 (49.6%) | 67 (50.4%) | ||
| > M1 | 23 | 12 (52.2%) | 11 (47.8%)0.025 | 13 (56.5%) | 10 (43.5%) | 19 (82.6%) | 4 (17.4%)0.003 | ||
| TIMP1 expression | |||||||||
| Low | 72 | 38 (52.8%) | 34 (47.2%) | -- | -- | 54 (63.5%) | 18 (24.7%) | ||
| Preserved | 86 | 13 (15.1%) | 73 (84.9%)0.001 | -- | -- | 31 (36.5%) | 55 (75.3%)0.001 | ||
NOTE: SCC, squamous cell carcinoma; ADC, adenocarcinoma; --, not applicable.
The data was analyzed by Pearson χ2 test. P values with statistical significance are as indicated.